BAVARIAN NORDIC A/S |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 186.2 DKK | +0.76% |
|
+3.47% | +4.96% |
| 05-31 | Bavarian Nordic Files for Supplemental US License for Smallpox-Monkeypox Vaccine | MT |
| 05-30 | Bavarian Nordic Gets $6.5 Million Funding for Development of Mpox Vaccine in Children | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Bavarian Nordic A/S specializes in the development, manufacturing and commercialization of cancer immunotherapies and vaccines for the prevention and treatment of infectious diseases.
Net sales by revenue source are divided between sales of products (97.8%) and services (2.2%).
Net sales are distributed geographically as follows: the United States (36.5%), Canada (22%), France (10.5%), Germany (10.1%), Spain (6.1%), Australia (4.8%), Switzerland ( 1.5%), Sweden (1%), Chile (0.9%), Taiwan (0.8%), the United Kingdom (0.6%), Hong Kong (0.2%), Saudi Arabia (0.1%), and others (4.9%).
Sector
Pharmaceuticals
Calendar
21/08/2024
- Q2 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
186.2
DKK
Average target price
262
DKK
Spread / Average Target
+40.67%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +4.96% | 2.09B | |
| +42.60% | 739B | |
| +32.34% | 598B | |
| -5.74% | 353B | |
| +17.79% | 318B | |
| +3.37% | 285B | |
| +16.47% | 240B | |
| +9.26% | 210B | |
| -5.07% | 206B | |
| +6.74% | 164B |
- Stock Market
- Equities
- BAVA Stock
- News Bavarian Nordic A/S
- US Plans to Approve Bavarian Nordic's Monkeypox Vaccine For Children